The court invites the claimant to select those attacks it considers the strongest and to rank them in order of importance. Once the attacks so selected are found to be unfounded, the Court considers it justified not to examin the remaining attacks. This places substantial responsibility on the parties as regards the selection and prioritisation of their objections.

The decision was issued in 12 months and revoked the DexCom patent, dismissing its infringement claim. The decision is now effective in the 17 EU Member States that have ratified the UPC Agreement; it may however be appealed.